Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HexAgon-HN: INBRX-106 + Keytruda vs Keytruda in first-line PD-L1-high recurrent/metastatic HNSCC
2024-515538-34-00Phase 3Authorised
- Sponsor
- Inhibrx Biosciences
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing INBRX-106 + Keytruda with Keytruda + placebo (2 arms). Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Jan 2025; status: authorised.
02
Drugs
inbrx-106pembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-515538-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515538-34-00.